

Vascular access in hemodialysis patients - registry data

Stojceva-Taneva O, Selim G

University Clinic of Nephrology, Medical Faculty of Skopje, University "Sts. Cyril and Methodius" Skopje, FYR of Macedonia

Abstract

Background: The use of arteriovenous fistula over a central venous catheter in hemodialysis patients is recommended whenever possible. It has become the gold standard among all the available permanent vascular accesses for hemodialysis as it is associated with less complications. The aim of our study was to analyze the type of vascular access in hemodialysis patients in our country, FYR of Macedonia and to see its association with other variables recorded by the National Renal Registry in 2009.

Material and methods: Data were collected by 18 hemodialysis centers in the country. A total of 1,457 patients were analyzed. One hundred and ninety one patients were incident, and 164 out of 1,457 died during the year. Except for 9 patients, all the others had data on type of vascular access, as well as data on any vascular access intervention performed during the year.

Results: The overall mean age was 58.8 ± 13.1 years. Eighty-nine percent of the non-incident patients (prevalent plus those who died during the year) had arteriovenous fistula, 10.6% central venous catheter and 0.2% vascular graft. When incident to non-incident patients were compared, incident patients were significantly older, had significantly higher mortality and significantly lower percentage of arteriovenous fistula. Patients with arteriovenous fistula had significantly longer dialysis vintage and significantly less deaths compared to those with central venous catheters.

Conclusions: The study showed that the number of non-incident hemodialysis patients with arteriovenous fistula in the country was high. The incident hemodialysis patients have high number of central venous catheters as vascular access for hemodialysis and significantly higher mortality compared to non-incident patients. Hippokratia 2014; 18 (3): 209-211.

Keywords: vascular access, hemodialysis, arteriovenous fistula

Corresponding author: Stojceva-Taneva Olivera, professor of internal medicine, Vodnjanska 17, 1000 Skopje, FYR of Macedonia, tel: +38923103713, e-mail: ostojevataneva@yahoo.com

Introduction

The major issue in the care of patients with End-Stage-Renal Failure (ESRF) treated by hemodialysis (HD) is the creation and maintenance of vascular access (VA). Vascular access is associated with surgical, economic and medical problems for the patients, as well as for their providers¹. The complications associated with HD, to a great extent are a result of the type of vascular access. The Dialysis Outcome Quality Initiative (DOQI) guidelines for VA in HD, recommend the use of arteriovenous fistula (AVF) over a central venous catheter whenever possible². According to these guidelines, arteriovenous grafts of synthetic or biologic material are acceptable, but not preferred, and long-term central venous catheters should be avoided. AVF has become the gold standard among all the available permanent VA for HD as it is associated with less complications. The guidelines recommend placement of fistula at least six months prior to anticipated start of HD in order to accomplish enough time for its maturation and to avoid eventual placement of central venous catheter. But, as many patients in the majority of countries in the world are not followed by

nephrologists prior to starting renal replacement therapy, they are confronted with lack of permanent VA placed timely, before initiating maintenance HD. The incidence of refusal of preemptive AVF is also high in a substantial group of chronic kidney disease patients³.

The aim of our study was to analyze the type of VA in HD patients in the country and to see its association with other variables recorded by the National Renal Registry in 2009 (age, gender, dialysis vintage and mortality)⁴.

Material and methods

The data collected by the National Renal Registry in 2009 were analyzed. All the prevalent patients from 18 HD centers in 2009 were included in the study, as well as those who died during the year (non-incident patients). A total of 1,457 patients were analyzed. One hundred and ninety one patients were incident, and 164 out of 1,457 died during the year. Except for 9 patients, all the others had data on type of VA, as well as data on any VA intervention performed during the year. The overall mean age was 58.8 ± 13.1 years. Distribution of type of VA was analyzed. Age, mortality, type of VA were compared

between incident and non-incident patients. Dialysis vintage was compared among the different type of VA. The number of interventions on VA during the year was analyzed, as well as number of deaths according to type of VA. Descriptive statistics to show distribution of VA was used. Student t-test for unpaired data was used to compare two groups of numeric variables, and ANOVA to compare more than two groups. Chi square test was used to compare two groups of nominative variables.

Results

A total of 153 patients were reported to have central venous catheters (10.6%). The majority of them were temporary (non-tunnelised catheters), but there are no data on the exact percentage. Eighty nine percent of patients on maintenance HD in 2009 had AVF (Figure 1). Figure 2 shows the coverage of different types of central venous catheters, subclavian, femoral, jugular and unknown type.

When non-incident to incident patients on HD were compared, it appeared that incident patients were significantly older, had higher mortality, had significantly lower rate of AVF as vascular access for HD and higher rate of central venous catheters (Table 1). Patients with central venous catheters had significantly lower dialysis vintage compared to those with AVF (Table 2). The majority of patients on HD in 2009, almost 94%, had no vascular intervention during the year (Table 3). Patients with central venous catheters had the highest rate of death during 2009 (Table 4). The patients who died in 2009 had significantly lower dialysis vintage and were significantly older than those who survived (Table 5). When males to females were compared, no significant difference was observed regarding mortality, vascular access type or dialysis vintage.




Figure 1: Type of vascular access in non-incident patients in 2009 in the country.

AVF: arteriovenous fistula, CVC: central venous catheter.




Figure 2: Percentage of different type of central venous catheters in prevalent hemodialysis patients (including those who died) in 2009.

SCC: subclavian catheter, FC: femoral catheter, JC: jugular catheter.

Table 1: Comparison of different type of vascular access, age and mortality, between incident and non-incident patients in 2009.

	191 incident patient	1266 non-incident patients	p
age	61.1 ± 13.2	58.4 ± 13.1	0.0087
died	32 (16.7%)	132 (10.4%)	0.009
AVF	132 (69.1%)	1,160 (92.3%)	<0.001
CVC	59 (30.9%)	94 (7.5%)	<0.001
graft	0 (0.0%)	3 (0.2%)	<0.001

AVF: arteriovenous fistula, CVC: central venous catheter.

Table 2: Comparison of dialysis vintage among patients on hemodialysis with different vascular accesses in 2009.

	Dialysis vintage	p
AVF	6.18 ± 6.1	<0.001
CVC	2.8 ± 4.3	<0.001
graft	11.0 ± 15.6	<0.001

AVF: arteriovenous fistula, CVC: central venous catheter.

Table 3: Number of vascular interventions during 2009.

Number of interventions (out of 1457, no data for 9 patients) n=1448	
1,358 (93.8%)	No vascular access intervention
70 (4.7%)	1 vascular access intervention
16 (1.1%)	2 vascular access interventions
4 (0.3%)	3 or more vascular access interventions

Table 4: Number of deaths according to type of vascular access.

	AVF	CVC	Graft	p
Number of deaths	9.67 %	24.84 %	0.0 %	0.0000

AVF: arteriovenous fistula, CVC: central venous catheter.

Table 5: Variables that significantly differed between the survived ones and those who died.

	Died	Survived	p
Dialysis vintage (years)	4.92 ± 5.6	5.94 ± 6.1	0.04
Age (years)	64.6 ± 12.2	58.0 ± 6.1	<0.001

Discussion

Type of vascular access in maintenance HD patients is of utmost importance as it is associated with numerous complications and patient survival. AVF is superior to arteriovenous prosthetic graft or tunneled central venous catheter, but in spite of different guidelines recommendations in favor of AVF as permanent vascular access in these patients, it is still underrepresented, not only in incident, but also in prevalent patients in many countries in the world. In the USA, the rate of use of AVF in prevalent patients is very small. It has increased remarkably from 32.2% to 55.8% in the period from 2003 to 2010, but is still much lower compared to European countries⁵. Pisoni et al, compared data for vascular access in HD patients in the period 1996-2000 between USA and European countries. AVF was used by 80% of European and 24% of US prevalent patients, and was significantly associated with younger age, male gender, lower body mass index, non-diabetic status, lack of peripheral vascular disease and no angina⁶. Similar results showed the DOPPS data from Canada indicating that Canadian chronic HD patients rely far too often on tunneled central venous catheters and are not reaching targets for AVF use, the reason possibly being that guidelines were not adequately disseminated in a way that targets the multiple physicians (family physicians, endocrinologists, cardiologists, internists, paediatricians, urologists, vascular and general surgeons, interventional radiologists and others), administrators and government health care policy makers⁷. In a recent paper by Krzanowski in Poland 46.5% of incident HD patients have AVF as permanent vascular access, and 84% of them have AVF at the end of the first year on HD⁸. The data from the Slovenian Renal Registry in 2008 show that VA was provided by a native AVF in 82%, a polytetrafluoroethylene graft in 6%, and a catheter in 12% of patients on HD⁹. Our data show remarkably high percentage of native AVF in prevalent HD patients (including those who died), more than 89%. Unlike other countries, for example the USA, where women are underrepresented among AVF patients, possibly because of concerns about smaller vascular diameters and higher rates of early primary fistula failure in female HD patients¹⁰, our data showed no significant gender differences among AVF patients. There were, also, no gender

differences regarding dialysis vintage and mortality.

Data obtained by our national renal registry show high number of prevalent patients with AVF as permanent vascular access. But, incident patients have substantially high percentage of central venous catheters and higher mortality. Therefore, efforts are to be undertaken for placing AVF prior to initiating renal replacement therapy in order to lower the number of complications of central venous catheters in incident HD patients as well as mortality.

Conflict of interest

Authors disclose no conflict of interest.

References

1. Abdel-Samad HM, El Samadoni A, Elsharkawi H. Early failure of native arterio-venous fistula for dialysis "a simple practical algorithm for prevention & treatment". *Kasr El Aini Journal of Surgery*. 2011; 12: 89-96.
2. National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. *Am J Kidney Dis*. 2006; 48 suppl 1: S1-S322.
3. Kimball TA, Barz K, Dimond KR, Edwards JM, Nehler MR. Efficacy of the kidney disease outcomes quality initiative guidelines for preemptive vascular access in an academic setting. *J Vasc Surg*. 2011; 54: 760-765.
4. ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2009. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands, 2011, available at: <http://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2009.pdf>, accessed on 28/02/2013
5. Wish JB. Vascular access for dialysis in the United States: progress, hurdles, controversies, and the future. *Semin Dial*. 2010; 23:614-618.
6. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, et al. Vascular access use in Europe and the United States: results from the DOPPS. *Kidney Int*. 2002; 61:305-316.
7. Mendelssohn DC, Ethier J, Elder SJ, Saran R, Port FK, Pisoni RL. Haemodialysis vascular access problems in Canada: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS II). *Nephrol Dial Transplant*. 2006; 21: 721-728.
8. Krzanowski M, Janda K, Chowaniec E, Kuśnierz-Cabala B, Sułowicz W. [Types of hemodialysis vascular access in patients on renal replacement therapy and its complications during a one year observation period]. *Przegl Lek*. 2011; 68: 343-347.
9. Buturović-Ponikvar J, Gubenšek J, Arnol M. Slovenian Renal Replacement Therapy Registry: excerpts from the 2008 Annual Report. *Ther Apher Dial*. 2011; 15: 228-233.
10. Marcus RJ, Marcus DA, Sureshkumar KK, Hussain SM, McGill RL. Gender differences in vascular access in hemodialysis patients in the United States: developing strategies for improving access outcome. *Gend Med*. 2007; 4: 193-204.